PE anti-human TACSTD2 (TROP2)
TACSTD2, also known as TROP-2, is a 35.7 kD protein that belongs to the EpCAM family. It is a cell surface receptor that can transduce calcium signals. Mutations of this gene are associated with gelatinous drop-like corneal dystrophy.
PRODUCT DETAILS
Clone: NY18
Antibody Type: Monoclonal
Reactivity: Human
Format: PE
Host: Mouse
Isotype: IgG2a, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
Original: $168.00
-70%$168.00
$50.40PE anti-human TACSTD2 (TROP2)
TACSTD2, also known as TROP-2, is a 35.7 kD protein that belongs to the EpCAM family. It is a cell surface receptor that can transduce calcium signals. Mutations of this gene are associated with gelatinous drop-like corneal dystrophy.
PRODUCT DETAILS
Clone: NY18
Antibody Type: Monoclonal
Reactivity: Human
Format: PE
Host: Mouse
Isotype: IgG2a, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
TACSTD2, also known as TROP-2, is a 35.7 kD protein that belongs to the EpCAM family. It is a cell surface receptor that can transduce calcium signals. Mutations of this gene are associated with gelatinous drop-like corneal dystrophy.
PRODUCT DETAILS
Clone: NY18
Antibody Type: Monoclonal
Reactivity: Human
Format: PE
Host: Mouse
Isotype: IgG2a, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
